Hematologic Malignancy
New approach ‘redefining what is a suitable donor’ for stem cell transplant
CHICAGO — Interim results from a phase 2 study showed positive survival outcomes for individuals who underwent peripheral blood stem cell transplantation for hematologic malignancies.
Racing modified cells against each other in humans may be the next step in gene therapies
The next evolution of gene therapies may involve pitting T cells with different modifications against one another in a “race” inside a human to determine which edits produce the best results against a tumor, an expert panel predicted.
Value of MRI, lumbar puncture questioned for immune cell-associated neurotoxicity syndrome
MRIs and lumbar punctures may not provide enough therapeutic value to be standard-of-care diagnostic tests in patients suffering neurologic symptoms following chimeric antigen receptor T-cell therapy.
Combining genomics, drug sensitivity testing could be ‘invaluable’ cancer treatment tool
An innovative combination of drug sensitivity testing and genomics helped identify therapeutic options for children with relapsed or refractory solid or hematologic malignancies, according to results published in Nature Medicine.
FDA approves earlier use of Abecma for triple-class exposed multiple myeloma
The FDA has approved Bristol Myers Squibb and 2seventy bio’s idecabtagene vicleucel for treatment of patients with triple-class exposed relapsed or refractory multiple myeloma, according to a company release.
‘We were shocked’: CAR-T rapidly reduces size of brain tumors in phase 1 trial
A novel bivalent-targeting, intrathecally delivered chimeric antigen receptor T-cell therapy decreased tumor size in patients with recurrent glioblastoma, according to results from a phase 1 study published in Nature Medicine.
FDA panel uses ’real talk’ to spotlight inspirations, challenges of Black oncologists
As a 10-year-old in Nashville, Tennessee, Ashley C. Woods, MD, watched her grandmother avoid medical treatment for metastatic lung cancer until it was too late.
Multi-engineered CAR-T confers significant, rapid reduction of aggressive brain tumor
A novel chimeric antigen receptor T-cell therapy produced significant tumor reductions in patients with glioblastoma, results from a phase 1 trial published in The New England Journal of Medicine showed.
Risk factors identified for secondary leukemia in patients who received CAR T cells
Researchers at Mayo Clinic have identified clinical factors associated with increased risk for developing myeloid neoplasms following chimeric antigen receptor T-cell therapy, according to data published in JAMA Oncology.
Those with blood cancers ‘can’t rely on vaccination’ for protection from severe COVID-19
Regardless of vaccination status, individuals with hematologic malignancies had increased odds of developing severe COVID-19 until oral antivirals became widely available in mid-2022, according to data published in JAMA Network Open.